Cyclin-Dependent Kinase 9 Activity Regulates Neutrophil Spontaneous Apoptosis

Article English OPEN
Wang, Keqing ; Hampson, Peter ; Hazeldine, Jon ; Krystof, Vladimir ; Strnad, Miroslav ; Pechan, Paul ; M., Janet (2012)
  • Publisher: Public Library of Science
  • Journal: PLoS ONE, volume 7, issue 1 (eissn: 1932-6203)
  • Related identifiers: doi: 10.1371/journal.pone.0030128, pmc: PMC3261871
  • Subject: Hematology | Research Article | Biology | Genetics | Molecular Cell Biology | Medicine | Immunity | Immunology

Neutrophils are the most abundant leukocyte and play a central role in the immune defense against rapidly dividing bacteria. However, they are also the shortest lived cell in the blood with a lifespan in the circulation of 5.4 days. The mechanisms underlying their short lifespan and spontaneous entry into apoptosis are poorly understood. Recently, the broad range cyclin-dependent kinase (CDK) inhibitor R-roscovitine was shown to increase neutrophil apoptosis, implicating CDKs in the regulation of neutrophil lifespan. To determine which CDKs were involved in regulating neutrophil lifespan we first examined CDK expression in human neutrophils and found that only three CDKs: CDK5, CDK7 and CDK9 were expressed in these cells. The use of CDK inhibitors with differing selectivity towards the various CDKs suggested that CDK9 activity regulates neutrophil lifespan. Furthermore CDK9 activity and the expression of its activating partner cyclin T1 both declined as neutrophils aged and entered apoptosis spontaneously. CDK9 is a component of the P-TEFb complex involved in transcriptional regulation and its inhibition will preferentially affect proteins with short half-lives. Treatment of neutrophils with flavopiridol, a potent CDK9 inhibitor, increased apoptosis and caused a rapid decline in the level of the anti-apoptotic protein Mcl-1, whilst Bcl2A was unaffected. We propose that CDK9 activity is a key regulator of neutrophil lifespan, preventing apoptosis by maintaining levels of short lived anti-apoptotic proteins such as Mcl-1. Furthermore, as inappropriate inhibition of neutrophil apoptosis contributes to chronic inflammatory diseases such as Rheumatoid Arthritis, CDK9 represents a novel therapeutic target in such diseases.
  • References (30)
    30 references, page 1 of 3

    1. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, et al. (2010) In vivo labeling with H20-H-2 reveals a human neutrophil lifespan of 5.4 days. Blood 116: 625-627.

    2. Brach MA, deVos S, Gruss HJ, Herrmann F (1992) Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colonystimulating factor is caused by inhibition of programmed cell death. Blood 80: 2920-2924.

    3. Raza K, Scheel-Toellner D, Lee CY, Pilling D, Curnow SJ, et al. (2006) Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Res Ther 8: R120.

    4. Leuenroth SJ, Grutkoski PS, Ayala A, Simms HH (2000) The loss of Mcl1 expression in human polymorphonuclear leukocytes promotes apoptosis. J Leukoc Biol 68: 158-166.

    5. Moulding DA, Quayle JA, Hart CA, Edwards SW (1998) Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 92: 2495-2502.

    6. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, et al. (2006) Cyclindependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 12: 1056-1064.

    7. Klausen P, Bjerregaard MD, Borregaard N, Cowland JB (2004) End-stage differentiation of neutrophil granulocytes in vivo is accompanied by upregulation of p27kip1 and down-regulation of CDK2, CDK4 and CDK6. J Leukoc Biol 75: 569-578.

    8. Leitch AE, Riley NA, Sheldrake TA, Festa M, Fox S, et al. (2010) The cyclindependent kinase inhibitor R-roscovitine down regulates Mcl-1 to overcome pro-inflammatory survival signalling and drive neutrophil apoptosis. Eur J Immunol 40: 1127-1138.

    9. Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, et al. (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 43: 2797-804.

    10. Johnson N, Bentley J, Wang L-Z, Newell DR, Robson CN, et al. (2010) Preclinical evaluation of cyclin-dependent kinase 1 and 2 inhibition in anti-estrogensensitive and resistant breast cancer cells. Br J Cancer 102: 342-350.

  • Metrics
    No metrics available
Share - Bookmark